Vontobel Holding Ltd. Acquires 25,121 Shares of Becton, Dickinson and Company $BDX

Key Points

• Vontobel Holding increased its Becton, Dickinson and Company stake by 27.5% in the third quarter, adding 25,121 shares to hold 116,608 shares valued at approximately $20.9 million. Institutional investors collectively own 86.97% of BDX.
• BD reported quarterly earnings of $3.23 per share, exceeding the $3.14 analyst consensus, while revenue reached $4.98 billion and rose 5.4% year over year. The company reaffirmed fiscal 2026 EPS guidance of $12.62–$12.72.
• BDX traded at $191.34, near its 52-week high, while analysts maintained a consensus “Hold” rating with an average price target of $185.07. The company pays a quarterly dividend of $1.05, yielding about 2.2% annually.

Vontobel Holding Ltd. raised its holdings in shares of Becton, Dickinson and Company (NYSE:BDX - Free Report) by 27.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 116,608 shares of the medical instruments supplier's stock after purchasing an additional 25,121 shares during the quarter. Vontobel Holding Ltd.'s holdings in Becton, Dickinson and Company were worth $20,873,000 as of its most recent SEC filing.

Several other institutional investors have also recently bought and sold shares of BDX. TD Waterhouse Canada Inc. boosted its stake in Becton, Dickinson and Company by 35.2% during the 3rd quarter. TD Waterhouse Canada Inc. now owns 130,042 shares of the medical instruments supplier's stock valued at $23,278,000 after purchasing an additional 33,831 shares during the last quarter. ARS Wealth Advisors Group LLC increased its holdings in Becton, Dickinson and Company by 2.9% during the 3rd quarter. ARS Wealth Advisors Group LLC now owns 30,255 shares of the medical instruments supplier's stock worth $5,416,000 after purchasing an additional 852 shares in the last quarter. Rise Advisors LLC bought a new stake in Becton, Dickinson and Company during the 3rd quarter worth approximately $51,000. Pension & Wealth Management Advisors Inc. raised its stake in shares of Becton, Dickinson and Company by 12.3% in the third quarter. Pension & Wealth Management Advisors Inc. now owns 510 shares of the medical instruments supplier's stock worth $94,000 after purchasing an additional 56 shares during the last quarter. Finally, Howard Capital Management LLC raised its stake in shares of Becton, Dickinson and Company by 15.0% in the third quarter. Howard Capital Management LLC now owns 1,954 shares of the medical instruments supplier's stock worth $350,000 after purchasing an additional 255 shares during the last quarter. Institutional investors and hedge funds own 86.97% of the company's stock.

Becton, Dickinson and Company Stock Performance

Shares of NYSE BDX traded down $2.42 during midday trading on Friday, reaching $191.34. The company's stock had a trading volume of 1,412,670 shares, compared to its average volume of 1,816,545. Becton, Dickinson and Company has a 12-month low of $127.59 and a 12-month high of $195.99. The firm has a 50 day moving average price of $184.03 and a 200-day moving average price of $163.70. The stock has a market capitalization of $52.72 billion, a P/E ratio of 57.63, a PEG ratio of 13.06 and a beta of 0.21. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.87 and a quick ratio of 0.51.

Becton, Dickinson and Company (NYSE:BDX - Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The medical instruments supplier reported $3.23 EPS for the quarter, beating analysts' consensus estimates of $3.14 by $0.09. The company had revenue of $4.98 billion during the quarter, compared to the consensus estimate of $4.89 billion. Becton, Dickinson and Company had a return on equity of 14.79% and a net margin of 4.52%. Becton, Dickinson and Company's revenue was up 5.4% on a year-over-year basis. During the same period last year, the business posted $3.68 earnings per share. Becton, Dickinson and Company has set its FY 2026 guidance at 12.620-12.720 EPS. As a group, equities analysts predict that Becton, Dickinson and Company will post 12.67 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, September 30th. Shareholders of record on Wednesday, September 9th were paid a $1.05 dividend. This represents a $4.20 dividend on an annualized basis and a yield of 2.2%. The ex-dividend date was Wednesday, September 9th. Becton, Dickinson and Company's dividend payout ratio is 126.51%.

Insider Activity

In other news, EVP Michael Feld sold 165 shares of the firm's stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $188.49, for a total transaction of $31,100.85. Following the completion of the sale, the executive vice president directly owned 19,720 shares of the company's stock, valued at $3,717,022.80. This trade represents a 0.83% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Roland Goette sold 2,438 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $180.84, for a total value of $440,887.92. Following the sale, the executive vice president owned 14,856 shares in the company, valued at $2,686,559.04. The trade was a 14.10% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 6,906 shares of company stock valued at $1,265,855 in the last ninety days. 0.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

BDX has been the topic of several analyst reports. Piper Sandler lifted their target price on Becton, Dickinson and Company from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Friday, August 7th. Weiss Ratings raised Becton, Dickinson and Company from a "sell (d+)" rating to a "hold (c-)" rating in a research report on Monday, September 28th. Evercore set a $180.00 price target on Becton, Dickinson and Company in a research report on Monday, July 6th. Bank of America raised their price objective on Becton, Dickinson and Company from $185.00 to $200.00 and gave the company a "neutral" rating in a research note on Monday, August 31st. Finally, Royal Bank Of Canada lifted their price objective on shares of Becton, Dickinson and Company from $180.00 to $190.00 and gave the stock a "sector perform" rating in a report on Thursday, August 13th. Seven research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Hold" and an average price target of $185.07.

About Becton, Dickinson and Company

Becton, Dickinson and Company, doing business as BD, is a global medical technology company that develops, manufactures and sells devices, diagnostic products and solutions for healthcare providers, researchers and patients. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, the company serves customers in hospitals, laboratories, physician offices, pharmacies and other healthcare settings worldwide.

BD's Medical segment offers products used for medication delivery and management, including needles, syringes, infusion systems, medication preparation and dispensing technologies, and systems designed to help improve medication safety.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.